Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures and commercialises medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced on Tuesday that the Phase 3 clinical study results for mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1) were orally presented (Abstract #: 306-OR) at the 85th Scientific Sessions of the American Diabetes Association (ADA), with Dr Lei Qian from Innovent Biologics as the presenter.

According to the company, the DREAMS-1 clinical study met its primary endpoint and all key secondary endpoints in July 2024. Mazdutide demonstrated dual benefits in glycaemic control and weight loss, along with comprehensive improvements in cardiovascular, renal, and metabolic indicators. Innovent said that these findings provide important evidence-based medical support for the use of next-generation GCG/GLP-1 receptor agonists in treating T2D.

In August 2024, mazdutide's NDA for glycemic control of T2D patients was accepted by China's National Medical Products Administration (NMPA) for review.